LIVIVO - Search results -

Search results

Result 1 - 10 of total 69

Search options

Article ; Online: Liver cyst mystery.

Musialik, Joanna / Kwaśniewska, Anna / Król, Robert / Ciupińska, Monika / Śnietura, Mirosław

2024 Volume 134, Issue 4

MeSH term(s)	Humans ; Cysts/diagnostic imaging ; Cysts/diagnosis ; Liver Diseases/diagnostic imaging ; Liver Diseases/diagnosis ; Female ; Male ; Middle Aged
Language	English
Publishing date	2024-02-16
Publishing country	Poland
Document type	Journal Article ; Case Reports
ZDB-ID	123500-x
ISSN	1897-9483 ; 0032-3772
ISSN (online)	1897-9483
ISSN	0032-3772
DOI	10.20452/pamw.16682
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 360: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Increased EBV DNAemia after Anti-SARS-CoV-2 Vaccination in Solid Organ Transplants.

Musialik, Joanna / Kolonko, Aureliusz / Więcek, Andrzej

Vaccines

2022 Volume 10, Issue 7

Abstract: The reactivation of latent viruses during SARS-CoV-2 infection is well recognized, and coinfection with Epstein−Barr virus (EBV) has been associated with severe clinical cases of COVID-19 infection. In transplant patients, EBV infection presents a ... ...

Abstract	The reactivation of latent viruses during SARS-CoV-2 infection is well recognized, and coinfection with Epstein−Barr virus (EBV) has been associated with severe clinical cases of COVID-19 infection. In transplant patients, EBV infection presents a significant challenge. Assessing the potential impact of SARS-CoV-2 vaccinations on EBV infections in stable kidney and liver transplant recipients was the objective of our study. Ten solid-organ-transplant (SOT) patients (eight kidney and two liver) vaccinated with standard doses of mRNA COVID-19 vaccines were included. EBV DNA viral load measurements were conducted prior to the vaccination and during a follow-up period (at the first month and after six months) after the second vaccine dose. After the second dose, a significant increase in median viremia was observed (p < 0.01) in 9 patients, and in one patient, the reactivation of EBV infection was found. Six months later, the median viremia decreased significantly (p < 0.05). The EBV viral load should be closely monitored as it could lead to the earlier diagnosis and treatment of EBV-related complications. Despite experiencing a decrease in the viral load six months post-vaccination, some patients still had a viral load over the baseline, which increased the risk of potential complications.
Language	English
Publishing date	2022-06-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines10070992
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Increased EBV DNAemia after Anti-SARS-CoV-2 Vaccination in Solid Organ Transplants

Joanna Musialik / Aureliusz Kolonko / Andrzej Więcek

Vaccines, Vol 10, Iss 7, p

2022 Volume 992

Abstract: The reactivation of latent viruses during SARS-CoV-2 infection is well recognized, and coinfection with Epstein–Barr virus (EBV) has been associated with severe clinical cases of COVID-19 infection. In transplant patients, EBV infection presents a ... ...

Abstract	The reactivation of latent viruses during SARS-CoV-2 infection is well recognized, and coinfection with Epstein–Barr virus (EBV) has been associated with severe clinical cases of COVID-19 infection. In transplant patients, EBV infection presents a significant challenge. Assessing the potential impact of SARS-CoV-2 vaccinations on EBV infections in stable kidney and liver transplant recipients was the objective of our study. Ten solid-organ-transplant (SOT) patients (eight kidney and two liver) vaccinated with standard doses of mRNA COVID-19 vaccines were included. EBV DNA viral load measurements were conducted prior to the vaccination and during a follow-up period (at the first month and after six months) after the second vaccine dose. After the second dose, a significant increase in median viremia was observed ( p < 0.01) in 9 patients, and in one patient, the reactivation of EBV infection was found. Six months later, the median viremia decreased significantly ( p < 0.05). The EBV viral load should be closely monitored as it could lead to the earlier diagnosis and treatment of EBV-related complications. Despite experiencing a decrease in the viral load six months post-vaccination, some patients still had a viral load over the baseline, which increased the risk of potential complications.
Keywords	Epstein–Barr virus ; solid organ transplant ; COVID-19 ; vaccine ; Medicine ; R
Subject code	610
Language	English
Publishing date	2022-06-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication.

Slonka, Justyna / Piotrowski, Damian / Janczewska, Ewa / Pisula, Arkadiusz / Musialik, Joanna / Jaroszewicz, Jerzy

Journal of clinical medicine

2022 Volume 11, Issue 11

Abstract: Chronic hepatitis C (CHC) is an ongoing epidemiological problem. The hepatitis C virus (HCV) may infect brain tissue, worsening mental health outcomes. The new era of highly effective oral Direct-Acting Agents (DAA) has brought a chance to eradicate the ... ...

Abstract	Chronic hepatitis C (CHC) is an ongoing epidemiological problem. The hepatitis C virus (HCV) may infect brain tissue, worsening mental health outcomes. The new era of highly effective oral Direct-Acting Agents (DAA) has brought a chance to eradicate the infection by 2030, however, screening campaigns are urgently needed as the majority of the infected are still undiagnosed. The aim of this study was to assess the prevalence of anxiety and depression among HCV patients, and the correlation with health-related quality of life (HRQoL) in the real-world setting, before and after DAA treatment. Data on anxiety, depression, and HRQoL, were collected by using self-reported questionnaires in a single center in Poland. The study group involved 90 respondents, 50% female, with a mean age of 43.8 years. HCV eradication decreased anxiety prevalence from 30.4% to 19.1% and depression from 35.2% to 18.2%. Significant improvement in 3 out of 4 of the WHOQOL-BREF (TheWorld Health Organization Quality of Life-BREF) domains and 8 out of 10 of the HQLQv.2 domains was obtained. Anxiety diminished the somatic domain scores by 3.5 (p < 0.0001), psychological by 2.3 (p = 0.0062), social by 1.75 (p = 0.0008), and environmental by 2.68 points (p = 0.0029). Depression diminished the somatic domain scores by 3.79 (p < 0.001), psychological by 2.23 (p < 0.001), social by 1.84 (p < 0.001), and environmental by 2.42 points (p = 0.004). In the Hepatitis Quality of Life Questionnaire version 2 (HQLQ v.2), the presence of depression and/or anxiety-impaired mental health, physical health, well-being, and vitality. These results indicate the need for an active search for HCV-infective people, especially among patients in psychiatric and psychological care.
Language	English
Publishing date	2022-05-28
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm11113044
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication

Justyna Slonka / Damian Piotrowski / Ewa Janczewska / Arkadiusz Pisula / Joanna Musialik / Jerzy Jaroszewicz

Journal of Clinical Medicine, Vol 11, Iss 3044, p

2022 Volume 3044

Abstract	Chronic hepatitis C (CHC) is an ongoing epidemiological problem. The hepatitis C virus (HCV) may infect brain tissue, worsening mental health outcomes. The new era of highly effective oral Direct-Acting Agents (DAA) has brought a chance to eradicate the infection by 2030, however, screening campaigns are urgently needed as the majority of the infected are still undiagnosed. The aim of this study was to assess the prevalence of anxiety and depression among HCV patients, and the correlation with health-related quality of life (HRQoL) in the real-world setting, before and after DAA treatment. Data on anxiety, depression, and HRQoL, were collected by using self-reported questionnaires in a single center in Poland. The study group involved 90 respondents, 50% female, with a mean age of 43.8 years. HCV eradication decreased anxiety prevalence from 30.4% to 19.1% and depression from 35.2% to 18.2%. Significant improvement in 3 out of 4 of the WHOQOL-BREF (TheWorld Health Organization Quality of Life-BREF) domains and 8 out of 10 of the HQLQv.2 domains was obtained. Anxiety diminished the somatic domain scores by 3.5 ( p < 0.0001), psychological by 2.3 ( p = 0.0062), social by 1.75 ( p = 0.0008), and environmental by 2.68 points ( p = 0.0029). Depression diminished the somatic domain scores by 3.79 ( p < 0.001), psychological by 2.23 ( p < 0.001), social by 1.84 ( p < 0.001), and environmental by 2.42 points ( p = 0.004). In the Hepatitis Quality of Life Questionnaire version 2 (HQLQ v.2), the presence of depression and/or anxiety-impaired mental health, physical health, well-being, and vitality. These results indicate the need for an active search for HCV-infective people, especially among patients in psychiatric and psychological care.
Keywords	hepatitis C ; depression ; anxiety ; GAD-7 ; PHQ-9 ; HQLQv.2 ; Medicine ; R
Subject code	360
Language	English
Publishing date	2022-05-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: First in Poland Simultaneous Liver-Lung Transplantation With Liver-First Approach for Recipient Due to Cystic Fibrosis: A Case Report.

Urlik, Maciej / Latos, Magdalena / Stącel, Tomasz / Wystrychowski, Wojciech / Joanna, Musialik / Nęcki, Mirosław / Antończyk, Remigiusz / Badura, Joanna / Horynecka, Zuzanna / Sekta, Sylwia / Król, Bogumiła / Gawęda, Martyna / Pandel, Anastazja / Zembala, Marian / Ochman, Marek / Król, Robert

Transplantation proceedings

2022 Volume 54, Issue 4, Page(s) 1171–1176

Abstract: Cystic fibrosis is an autosomal progressive disease affecting the lung, pancreas, and liver. Some patients develop end-stage respiratory and liver failure. For such patients, combined lung-liver transplantation remains the only therapeutic option. In ... ...

Abstract	Cystic fibrosis is an autosomal progressive disease affecting the lung, pancreas, and liver. Some patients develop end-stage respiratory and liver failure. For such patients, combined lung-liver transplantation remains the only therapeutic option. In this article we present the first simultaneous lung-liver transplantation in Poland, as well as in Central and Eastern Europe, with detailed clinical history, surgical aspects, and postoperative course.
MeSH term(s)	Cystic Fibrosis/complications ; Cystic Fibrosis/surgery ; Humans ; Liver ; Liver Transplantation ; Lung/surgery ; Lung Transplantation ; Poland
Language	English
Publishing date	2022-05-18
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	82046-5
ISSN	1873-2623 ; 0041-1345
ISSN (online)	1873-2623
ISSN	0041-1345
DOI	10.1016/j.transproceed.2022.02.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 835: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical insights into the role of immunosuppression in solid organ transplant recipients with COVID-19.

Kolonko, Aureliusz / Kuczaj, Agnieszka A / Musialik, Joanna / Słabiak-Błaż, Natalia / Hrapkowicz, Tomasz / Przybyłowski, Piotr / Więcek, Andrzej

Polish archives of internal medicine

2021 Volume 132, Issue 2

Abstract: Introduction: The COVID-19 pandemic has disproportionately affected patients who have undergone solid organ transplantation (SOT).: Objectives: We aimed to assess a cohort of transplant recipients who developed COVID‑19, with a focus on ... ...

Abstract	Introduction: The COVID-19 pandemic has disproportionately affected patients who have undergone solid organ transplantation (SOT). Objectives: We aimed to assess a cohort of transplant recipients who developed COVID‑19, with a focus on immunosuppressive regimen, blood tacrolimus levels, clinical course, and patient and graft outcomes. Patients and methods: During the first 12 months of the pandemic, we identified ambulatory SOT recipients, including kidney, liver, and heart transplant recipients, diagnosed with SARS‑CoV‑2 infection. Baseline and follow‑up data on graft function, immunosuppression, and patient and graft outcomes were assessed. Results: Of the 2091 ambulatory patients, we identified 201 transplant recipients (9.6%) with SARS‑CoV‑2 infection (kidney transplant, n = 112; heart transplant, n = 56; liver transplant, n = 33). Patients after recent kidney (during 2015-2020) or heart (during 2020) transplant were significantly more often diagnosed with COVID ‑19 than patients with a longer time since transplant. Additionally, blood trough tacrolimus levels measured during or shortly after COVID‑19 in 23 kidney graft recipients were significantly increased by a median of 76.1% (interquartile range, 47.4%-109.4%) relative to predose trough levels. However, liver function parameters were not elevated, necessitating a tacrolimus dose reduction in 73.9% of the patients. Conclusions: In our study, kidney transplant recipients showed significant disturbances of tacrolimus metabolism, which may account for kidney function worsening during COVID‑19. Moreover, infection was more common in patients with recent kidney or heart transplant, which suggests that the level of immunosuppression may affect morbidity related to SARS‑CoV‑2 infection.
MeSH term(s)	COVID-19 ; Humans ; Immunosuppression Therapy/adverse effects ; Immunosuppressive Agents/adverse effects ; Organ Transplantation/adverse effects ; Pandemics ; SARS-CoV-2 ; Transplant Recipients
Chemical Substances	Immunosuppressive Agents
Language	English
Publishing date	2021-11-15
Publishing country	Poland
Document type	Journal Article
ZDB-ID	123500-x
ISSN	1897-9483 ; 0032-3772
ISSN (online)	1897-9483
ISSN	0032-3772
DOI	10.20452/pamw.16139
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 360: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation.

Musialik, Joanna / Kolonko, Aureliusz / Kwiecień, Katarzyna / Owczarek, Aleksander J / Więcek, Andrzej

Transplant infectious disease : an official journal of the Transplantation Society

2019 Volume 21, Issue 3, Page(s) e13090

Abstract: Background: Direct-acting antivirals (DAAs), including sofosbuvir (SOF), are recommended for treatment of chronic hepatitis C virus (HCV) infection. However, few studies have investigated the effectiveness and safety of new DAAs in kidney transplant ... ...

Abstract	Background: Direct-acting antivirals (DAAs), including sofosbuvir (SOF), are recommended for treatment of chronic hepatitis C virus (HCV) infection. However, few studies have investigated the effectiveness and safety of new DAAs in kidney transplant recipients (KTRs). Objectives: To assess the effectiveness and safety of SOF-based therapy in stable KTRs. Patients and methods: Forty KTRs were treated with SOF-based regimens. Rapid, end-therapeutic, and sustained virologic responses were assessed, as was liver stiffness by elastometry. Safety was monitored by measuring the estimated glomerular filtration rate (eGFR), blood hemoglobin (Hb) concentration, proteinuria, and blood trough levels of calcineurin inhibitors (CNIs). Other side effects were also recorded. Results: The effectiveness of DAAs was 100% at all time points. The therapy did not significantly influence eGFR or proteinuria, but significantly decreased mean blood Hb levels (13.5 ± 2.0 vs 11.6 ± 1.9, respectively, P < 0.001), which required a dose reduction or cessation of ribavirin (RBV) in 50% of patients. A profound, significant decrease in initial CNI concentrations was also observed during treatment in the majority of patients within the first month of therapy. Conclusions: In this cohort of KTRs, the new SOF-based therapies were characterized by 100% effectiveness and good safety profiles. However, in patients co-treated with RBV, close blood Hb monitoring and early RBV dose reduction are necessary. In the majority of KTRs, antiviral therapy leads to a substantial and early decrease in CNIs levels, thus frequent measurement of CNI levels is necessary during SOF-based therapy.
MeSH term(s)	Adult ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Calcineurin Inhibitors/blood ; Cohort Studies ; Drug Therapy, Combination ; Female ; Glomerular Filtration Rate ; Hepatitis C, Chronic/drug therapy ; Humans ; Immunosuppressive Agents/therapeutic use ; Kidney Transplantation ; Liver/virology ; Male ; Middle Aged ; Sofosbuvir/adverse effects ; Sofosbuvir/therapeutic use ; Treatment Outcome
Chemical Substances	Antiviral Agents ; Calcineurin Inhibitors ; Immunosuppressive Agents ; Sofosbuvir (WJ6CA3ZU8B)
Language	English
Publishing date	2019-04-25
Publishing country	Denmark
Document type	Journal Article
ZDB-ID	1476094-0
ISSN	1399-3062 ; 1398-2273
ISSN (online)	1399-3062
ISSN	1398-2273
DOI	10.1111/tid.13090
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5100: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Unexpected characteristics of cirrhotic liver tumors.

Kwiecień, Katarzyna / Musialik, Joanna / Król, Robert / Kwaśniewska, Anna / Paleń, Piotr / Więcek, Andrzej

Polish archives of internal medicine

2018 Volume 128, Issue 3, Page(s) 187–188

MeSH term(s)	Carcinoma, Hepatocellular/diagnostic imaging ; Carcinoma, Hepatocellular/etiology ; Hepatitis C/complications ; Humans ; Liver Cirrhosis/complications ; Liver Cirrhosis/etiology ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/etiology ; Male ; Middle Aged
Language	English
Publishing date	2018-03-26
Publishing country	Poland
Document type	Case Reports ; Journal Article
ZDB-ID	123500-x
ISSN	1897-9483 ; 0032-3772
ISSN (online)	1897-9483
ISSN	0032-3772
DOI	10.20452/pamw.4229
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 360: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Eosinophilia in patient with acute cellular rejection after liver transplantation--case presentation and literature overview.

Musialik, Joanna / Karkoszka, Henryk / Wiecek, Andrzej

Przeglad lekarski

2015 Volume 72, Issue 6, Page(s) 321–324

Abstract: Acute cellular rejection (ACR) is still an important problem affecting patients after liver transplantation. Early diagnosis is necessary for initiate treatment, but there are not simple, noninvasive methods to confirm the diagnosis, and up to now, the ... ...

Abstract	Acute cellular rejection (ACR) is still an important problem affecting patients after liver transplantation. Early diagnosis is necessary for initiate treatment, but there are not simple, noninvasive methods to confirm the diagnosis, and up to now, the gold standard in the evaluation of ACR is liver biopsy. The blood eosinophilia seems to be a promising tool supporting the diagnosis and monitoring the effectiveness of ACR treatment in patients after liver transplantation. In this paper a young patient transplanted due to primary sclerosing cholagitis with blood and graft eosinophilia is presented. Based on this interesting case, the literature overview is presented. We conclude that blood eosinophilia, especially with concomitant increase of gamma-glutamyl transpeptidase activity and bilirubin concentration could be an effective tool to predict ACR and may help to choose the.
MeSH term(s)	Adult ; Bilirubin/blood ; Eosinophilia/diagnosis ; Graft Rejection/diagnosis ; Graft Rejection/etiology ; Humans ; Liver Transplantation/adverse effects ; gamma-Glutamyltransferase/blood
Chemical Substances	gamma-Glutamyltransferase (EC 2.3.2.2) ; Bilirubin (RFM9X3LJ49)
Language	English
Publishing date	2015
Publishing country	Poland
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	414053-9
ISSN	0033-2240 ; 0860-0422
ISSN	0033-2240 ; 0860-0422
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 640: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito